1. Home
  2. LOOP vs ACRV Comparison

LOOP vs ACRV Comparison

Compare LOOP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$1.19

Market Cap

56.2M

Sector

Industrials

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.08

Market Cap

64.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOOP
ACRV
Founded
2010
2018
Country
Canada
United States
Employees
N/A
78
Industry
Major Chemicals
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
64.7M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
LOOP
ACRV
Price
$1.19
$2.08
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$13.00
AVG Volume (30 Days)
63.8K
3.5M
Earning Date
01-14-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,146,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$41.40
$805.34
P/E Ratio
N/A
N/A
Revenue Growth
8746.03
N/A
52 Week Low
$0.85
$1.05
52 Week High
$2.29
$8.00

Technical Indicators

Market Signals
Indicator
LOOP
ACRV
Relative Strength Index (RSI) 57.87 47.62
Support Level $1.08 $1.57
Resistance Level $1.21 $2.19
Average True Range (ATR) 0.06 0.32
MACD 0.01 -0.01
Stochastic Oscillator 83.37 25.13

Price Performance

Historical Comparison
LOOP
ACRV

About LOOP Loop Industries Inc.

Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: